{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T16:32:07Z","timestamp":1793205127564,"version":"4.5.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","gynecologiconcology-online.net","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.ygyno.2023.05.063","type":"journal-article","created":{"date-parts":[[2023,5,24]],"date-time":"2023-05-24T13:02:35Z","timestamp":1684933355000},"page":"239-246","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"special_numbering":"C","title":["WEE1 inhibitor adavosertib in combination with carboplatin in advanced TP53 mutated ovarian cancer: A biomarker-enriched phase II study"],"prefix":"10.1016","volume":"174","author":[{"given":"Alaa","family":"Embaby","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Kutzera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill J.","family":"Geenen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dick","family":"Pluim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Hofland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joyce","family":"Sanders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Lopez-Yurda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos H.","family":"Beijnen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alwin D.R.","family":"Huitema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petronella O.","family":"Witteveen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeltje","family":"Steeghs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gijs","family":"van Haaften","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel A.T.M.","family":"van Vugt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeroen","family":"de Ridder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frans L.","family":"Opdam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2023.05.063_bb0005","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ygyno.2023.05.063_bb0010","doi-asserted-by":"crossref","first-page":"287","DOI":"10.2147\/IJWH.S197604","article-title":"Ovarian cancer in the world: epidemiology and risk factors","volume":"11","author":"Momenimovahed","year":"2019","journal-title":"Int. J. Women\u2019s Health"},{"key":"10.1016\/j.ygyno.2023.05.063_bb0015","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/annonc\/mdz062","article-title":"ESMO\u2013ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease\u2020\u2020","volume":"30","author":"Colombo","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2023.05.063_bb0020","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1007\/s11864-022-00938-4","article-title":"Appropriate selection of PARP inhibitors in ovarian Cancer","volume":"23","author":"Smith","year":"2022","journal-title":"Curr. Treat. Options in Oncol."},{"key":"10.1016\/j.ygyno.2023.05.063_bb0025","doi-asserted-by":"crossref","first-page":"186","DOI":"10.2174\/157488410791498824","article-title":"Abrogation of the G2 checkpoint by inhibition of Wee-1 kinase results in sensitization of p53-deficient tumor cells to DNA-damaging agents","volume":"5","author":"Leijen","year":"2010","journal-title":"Curr. Clin. Pharmacol."},{"key":"10.1016\/j.ygyno.2023.05.063_bb0030","doi-asserted-by":"crossref","first-page":"3159","DOI":"10.4161\/cc.26062","article-title":"Wee1 kinase as a target for cancer therapy","volume":"12","author":"Do","year":"2013","journal-title":"Cell Cycle"},{"key":"10.1016\/j.ygyno.2023.05.063_bb0035","doi-asserted-by":"crossref","first-page":"514","DOI":"10.4161\/cbt.9.7.11115","article-title":"MK-1775, a small molecule Wee1 inhibitor, enhances anti-tumor efficacy of various DNA-damaging agents, including 5-fluorouracil","volume":"9","author":"Hirai","year":"2010","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.ygyno.2023.05.063_bb0040","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.1158\/1535-7163.MCT-09-0463","article-title":"Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents","volume":"8","author":"Hirai","year":"2009","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ygyno.2023.05.063_bb0045","doi-asserted-by":"crossref","first-page":"4371","DOI":"10.1200\/JCO.2016.67.5991","article-title":"Phase I study evaluating WEE1 inhibitor AZD1775 as monotherapy and in combination with gemcitabine, cisplatin, or carboplatin in patients with advanced solid tumors","volume":"34","author":"Leijen","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2023.05.063_bb0050","doi-asserted-by":"crossref","first-page":"4354","DOI":"10.1200\/JCO.2016.67.5942","article-title":"Phase II study of WEE1 inhibitor AZD1775 plus carboplatin in patients with TP53-mutated ovarian cancer refractory or resistant to first-line therapy within 3 months","volume":"34","author":"Leijen","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2023.05.063_bb0055","article-title":"CCNE1 amplification as a predictive biomarker of chemotherapy resistance in epithelial ovarian cancer","volume":"10","author":"Gorski","year":"2020","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.ygyno.2023.05.063_bb0060","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","author":"Bell","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.ygyno.2023.05.063_bb0065","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ygyno.2023.05.063_bb0070","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.1989.7.11.1748","article-title":"Carboplatin dosage: prospective evaluation of a simple formula based on renal function","volume":"7","author":"Calvert","year":"1989","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2023.05.063_bb0075","series-title":"Common Terminology Criteria for Adverse Events (CTCAE) version 4.03","year":"2023"},{"key":"10.1016\/j.ygyno.2023.05.063_bb0080","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1200\/JCO.2006.09.6735","article-title":"Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer","volume":"25","author":"Mutch","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2023.05.063_bb0085","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.ygyno.2014.02.038","article-title":"\u201cPlatinum resistant\u201d ovarian cancer: what is it, who to treat and how to measure benefit?","volume":"133","author":"Davis","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2023.05.063_bb0090","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/cyto.a.22049","article-title":"Validation of a multiparameter flow cytometry method for the determination of phosphorylated extracellular-signal-regulated kinase and DNA in circulating tumor cells","volume":"81","author":"Pluim","year":"2012","journal-title":"Cytometry A"},{"key":"10.1016\/j.ygyno.2023.05.063_bb0095","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/s41586-019-1689-y","article-title":"Pan-cancer whole-genome analyses of metastatic solid tumours","volume":"575","author":"Priestley","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.ygyno.2023.05.063_bb0100","series-title":"Brian: Genomics in the Cloud: Using Docker, GATK, and WDL in Terra","author":"Van der Auwera","year":"2020"},{"key":"10.1016\/j.ygyno.2023.05.063_bb0105","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1093\/bioinformatics\/bts271","article-title":"Strelka: accurate somatic small-variant calling from sequenced tumor-normal sample pairs","volume":"28","author":"Saunders","year":"2012","journal-title":"Bioinformatics"},{"key":"10.1016\/j.ygyno.2023.05.063_bb0110","series-title":"GRIDSS: Sensitive and Specific Genomic Rearrangement Detection Using Positional de Bruijn Graph Assembly","first-page":"2050","volume":"27","author":"Cameron","year":"2017"},{"key":"10.1016\/j.ygyno.2023.05.063_bb0115","series-title":"PURPLE tool - Purity Ploidy Estimator for Whole Genome Sequenced (WGS) Data","year":"2023"},{"key":"10.1016\/j.ygyno.2023.05.063_bb0120","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.cell.2017.09.042","article-title":"Universal patterns of selection in Cancer and somatic tissues","volume":"171","author":"Martincorena","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.ygyno.2023.05.063_bb0125","doi-asserted-by":"crossref","first-page":"5584","DOI":"10.1038\/s41467-020-19406-4","article-title":"Pan-cancer landscape of homologous recombination deficiency","volume":"11","author":"Nguyen","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ygyno.2023.05.063_bb0135","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13000-023-01317-9","article-title":"A comprehensive immunohistochemical analysis of 26 markers in 250 cases of serous ovarian tumors","volume":"18","author":"N\u011bmejcov\u00e1","year":"2023","journal-title":"Diagn. Pathol."},{"key":"10.1016\/j.ygyno.2023.05.063_bb0140","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1309\/AJCPUXLP7XD8OQYY","article-title":"The LAST guidelines in clinical practice: implementing recommendations for p16 use","volume":"144","author":"Clinton","year":"2015","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.ygyno.2023.05.063_bb0145","series-title":"IGNITE: A Phase II Signal-Seeking Trial of Adavosertib Targeting Recurrent High-grade, Serous Ovarian Cancer with Cyclin E1 Overexpression with and Without Gene Amplification","first-page":"5515","volume":"40","author":"Au-Yeung","year":"2022"},{"key":"10.1016\/j.ygyno.2023.05.063_bb0150","series-title":"Distinct Genomic Profiles are Associated with Treatment Response and Survival in Ovarian Cancer","first-page":"1511","volume":"14","author":"de Witte","year":"2022"},{"key":"10.1016\/j.ygyno.2023.05.063_bb0155","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial","volume":"32","author":"Pujade-Lauraine","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2023.05.063_bb0160","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1158\/1078-0432.CCR-21-0158","article-title":"Adavosertib with chemotherapy in patients with primary platinum-resistant ovarian, fallopian tube, or peritoneal cancer: an open-label, four-arm, Phase II Study","volume":"28","author":"Moore","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2023.05.063_bb0165","doi-asserted-by":"crossref","first-page":"3834","DOI":"10.1158\/1078-0432.CCR-21-0329","article-title":"Safety, antitumor activity, and biomarker analysis in a phase I trial of the once-daily Wee1 inhibitor Adavosertib (AZD1775) in patients with advanced solid tumors","volume":"27","author":"Takebe","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2023.05.063_bb0170","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0140-6736(20)32554-X","article-title":"Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"397","author":"Lheureux","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2023.05.063_bb0175","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/cjp2.109","article-title":"Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an ovarian tumor tissue analysis consortium study","volume":"4","author":"Rambau","year":"2018","journal-title":"J. Pathol. Clin. Res."},{"key":"10.1016\/j.ygyno.2023.05.063_bb0180","series-title":"Combined CCNE1 High-level Amplification and Overexpression is Associated with Unfavourable Outcome in Tubo-ovarian High-grade Serous Carcinoma","first-page":"252","volume":"6","author":"Chan","year":"2020"},{"key":"10.1016\/j.ygyno.2023.05.063_bb0185","doi-asserted-by":"crossref","first-page":"4767","DOI":"10.1158\/1078-0432.CCR-20-0219","article-title":"A biomarker-enriched, randomized phase II trial of Adavosertib (AZD1775) plus paclitaxel and carboplatin for women with platinum-sensitive TP53-mutant ovarian cancer","volume":"26","author":"Oza","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2023.05.063_bb0190","series-title":"Abstract 974: Phase II Trial of the Wee1 Inhibitor Adavosertib in Advanced Refractory Solid Tumors with CCNE1 Amplification","author":"Fu","year":"2021"},{"key":"10.1016\/j.ygyno.2023.05.063_bb0195","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s12032-017-0960-z","article-title":"A brief review of the management of platinum-resistant-platinum-refractory ovarian cancer","volume":"34","author":"Oronsky","year":"2017","journal-title":"Med. Oncol."},{"key":"10.1016\/j.ygyno.2023.05.063_bb0200","series-title":"No Place for Wee1 in Astra\u2019s Synthetic Lethality Work","year":"2022"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825823003049?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825823003049?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T20:53:08Z","timestamp":1715806388000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825823003049"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":39,"alternative-id":["S0090825823003049"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2023.05.063","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"WEE1 inhibitor adavosertib in combination with carboplatin in advanced TP53 mutated ovarian cancer: A biomarker-enriched phase II study","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2023.05.063","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}